Why the study?
Does celiprolol improve cardiovascular risk profile and quality of life compared to conventional beta-blockers in patients with mild to moderate hypertension?
Does celiprolol improve cardiovascular risk profile and quality of life compared to conventional beta-blockers in patients with mild to moderate hypertension?
This article examines manufacturer claims regarding the efficacy and quality of life benefits of celiprolol for mild to moderate hypertension.
Highlights need to verify manufacturer claims on celiprolol; leaves open its role versus conventional beta-blockers.
Celiprolol (Celectol – Rhoône Poulenc Rorer) is a new cardioselective β-blocker and vasodilator, intended for once daily treatment of mild to moderate hypertension. The manufacturer claims that “it improves the overall cardiovascular risk profile” and gives hypertensive patients “a better quality of life than can be expected from conventional β-blocker treatment”. We examine these claims.
No takes yet. Share an insight, caveat, or question.
A 1992 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: